Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$32.54 -2.04%

-$1.24 today

Market cap
$933.51M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.86M

Average 1.00M

Returns on capital

Nektar Therapeutics management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-182.6%

avg -213.3%

ROIC

-52.8%

avg -24.4%

ROA

-58.5%

avg -31.6%

Analysis

ROIC is currently the strongest return metric at -52.8% versus its period average of -24.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Howard W. Robin

Chief Executive Officer, President & DirectorUSD 2.33M7354.63K0.28%

Jonathan Zalevsky

Senior Vice President and Chief Research & Development OfficerUSD 1.19M519.57K0.05%

Linda Rubinstein

Chief Financial Officer and Principal Financial & Accounting OfficerUSD 460.85K59——

Ken Franke

Senior Vice President of Biologics Process Development & Manufacturing————

Mary Tagliaferri

Chief Medical Officer—60——

Spilios Asimakopoulos

Vice President of Commercial Strategy & Marketing————

Elizabeth Zhang

VP of Legal, Corporate Counsel & Secretary————

Jennifer Ruddock

Chief Business Officer————

Robert Bacci

Chief People Officer and Head of Quality & Facilities————

Jason Barnard

Chief Accounting Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 18, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

16

$2.43M

Net Transaction Value

−$2.43M

Net selling

Most Active

ROBIN HOWARD W

8 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 18, 26

Zalevsky Jonathan

Direct

Sell$13.4K
Aug 18, 26

ROBIN HOWARD W

Direct

Sell$30.1K
Jun 30, 26

Zalevsky Jonathan

Direct

Sell$397.7K
Jun 17, 26

ROBIN HOWARD W

Direct

Sell$334.5K
Jun 17, 26

ROBIN HOWARD W

Direct

Sell$277.4K
Jun 16, 26

ROBIN HOWARD W

Direct

Sell$318K
Jun 16, 26

ROBIN HOWARD W

Direct

Sell$285.2K
Jun 15, 26

Zalevsky Jonathan

Direct

Sell$336.2K
May 19, 26

Zalevsky Jonathan

Direct

Sell$13K
May 19, 26

ROBIN HOWARD W

Direct

Sell$29.1K

1–10 of 16

Summary

Insiders reported 0 buys worth $0.00 and 16 sells worth $2.43M over the last 12 months. That adds up to net selling of $2.43M. ROBIN HOWARD W was the most active insider with 8 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A11 analysts
RevenueN/AN/A-15.7%
+27.4% (5yr)12 analysts
Net IncomeN/AN/AN/A
N/A12 analysts
EBITN/AN/AN/A
N/A12 analysts

Analysis

Recent growth has been strongest in Revenue at -15.7% over three years. Forward estimates point to Revenue at +27.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Nektar Therapeutics compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about NKTR's management, answered from reported figures.

Who manages NKTR?

Nektar Therapeutics (NKTR) lists 10 active executives. The top listed executive is Ken Franke, Senior Vice President of Biologics Process Development & Manufacturing.

Are NKTR insiders buying or selling?

Recent insider activity shows net buying of $34.74M.